在患有高胰岛素症的儿童中,奥克胺的疗效和安全性:来自中国两个中心的证据
Jinwen Ni1, Bingyan Cao2, He Zeng3
1Department of Pediatric Endocrinology and Inherited Metabolic Diseases, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, 201102, China.
European journal of pediatrics
|November 20, 2024
概括
在对其他疗法的反应不佳的患者中,Octreotide有效治疗先天性高胰岛素症 (CHI). 较低的奥克胺剂量与较少的不良事件有关,这表明需要仔细监测剂量.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 医学药理学 医学药理学
背景情况:
- 奥克胺是对先天性高胰岛素症 (CHI) 的关键二线疗法.
- 胃肠道问题是奥克胺治疗的常见副作用.
- 有限的数据存在于大量的CHI患者队列中关于octreotide的安全性.
研究的目的:
- 评估中国CHI患者中奥克胺的安全性和有效性.
- 为了确定奥克胺剂量与不良事件发生率之间的关系.
主要方法:
- 在中国两个主要医疗中心对122名CHI患者进行了逆向分析,这些患者接受了奥克胺治疗.
- 评估不良事件,治疗成功率和剂量参数.
- 通过不同剂量范围比较的不良事件率.
主要成果:
- 在治理CHI方面,Octreotide取得了93%的成功率.
- 常见的副作用包括肝胆道损伤 (20.5%),胃肠道症状 (31.1%),过渡性高血糖症 (49.2%).
- 副作用发生率是剂量依赖的,从58%的5-10μg/kg/天增加到100%的20μg/kg/天以上.
结论:
- 在对二氧化无反应的患者中,奥克特雷奥提德是有效的治疗CHI,没有发现严重的不良影响.
- 中间的八二胺剂量与较低的不良事件发生率相关.
- 建议在启动和定位octreotide期间密切监测患者.
相关概念视频
01:16Insulin: Dosing Regimen and Adverse Effects
145
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
145
01:24Glucagon-like Receptor Agonists
298
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
298